Abstract. The van Elteren (vE) test, a stratified Wilcoxon-Mann-Whitney test, is a widely used nonparametric method for comparing two treatments adjusting for stratum effects. Although the vE test produces a p-value for testing the null hypothesis of no treatment effect, additional heuristic methods need to be used to determine which treatment is better. Moreover, such heuristic methods may lead to inconclusive decisions in some situations. Furthermore, it is unclear on how to quantify treatment effect size when the van Elteren test is used. In this paper, we define a competing probability (CP) inherently related to the vE test and derive point and interval estimators for CP. The CP serves as an effect size measure and can be used to determine which treatment is better by comparing the CP with 0.5.
Introduction
For continuous or ordinal response variables, the van Elteren (vE) test [9] is a commonly used nonparametric method for comparing treatments while adjusting for stratum effect. Examples of use of the vE test include ecological studies [4] , epidemiological studies [6] , and clinical trials [2] . Recently the vE test caught much research interest. For example, see Zhao [11] and Zhao et al. [12] for sample size and power calculations for the vE test and Qu et al. [8] for recommendations on choosing between the vE test and its un-stratified version, the Wilcoxon-Mann-Whitney (WMW) test [7, 10] .
The vE test can be formulated as follows. Suppose we observe data collected for two treatments (A and B) in S strata. For k = 1, . . . , S, let x k = (x k,1 , . . . , x k,m k ) and y k = (y k,1 , . . . , y k,n k ) be independent random samples drawn from Treatments A and B, respectively. Also, denote the cumulative distribution functions (CDF) for the two random samples as F k and G k , respectively. For the kth stratum, the Mann-Whitney U statistic is We next define weight c k = 1/(N k + 1), where N k = m k + n k . Then, the vE statistic is a weighted sum of the individual U statistics U k with c k as the weights:
Asymptotically, the standardized vE statistic has a standard normal distribution:
Because typically only the vE statistic and its corresponding p-value are reported for analyzing a particular dataset, traditionally other summary statistics need to be examined to determine which treatment is better when a significant vE p-value is observed. For example, Cardozo et al. [2] reported that the vE p-value was less than a pre-specified 0.05 α-level for testing the percent reduction in Incontinence Episode Frequency (IEF) between duloxetine and placebo stratified by baseline severity. In addition, the median percent reductions in IEF were 60% and 27% for duloxetine and placebo, respectively. Therefore, they concluded that duloxetine is more efficacious than placebo in this study. Note that the median reductions in IEF by baseline severity were not reported in this article. Otherwise, by comparing these medians between duloxetine and placebo by baseline severity would provide even more evidence that duloxetine is better than placebo.
Although examining medians works well in the previous example, it may not work in other cases. For the WMW test which is a special case of the vE test, the WMW test can have a p-value near 0.00 while the two treatments have identical sample medians. Similar problem arises when the response variable is ordinal and contingency table proportions are examined as a way to determine which treatment is better. The fundamental reason for these difficulties is these aforementioned heuristic methods are relevant but not inherently related to the vE statistic.
Therefore, in this paper, we intend to solve these problems and to achieve two goals. First, we aim to define a quantity that is inherently related to the vE statistic. When a significant vE p-value is observed, examining a point estimate of this quantity can reveal which treatment is better. In addition, we want this quantity to reduce to a known one when the number of strata is 1, in which case the vE statistic reduces to the WMW statistic. Second, we aim to develop a confidence interval estimator for this quantity.
The remainder of the paper is organized as follows. In Section 2 we define a competing probability (CP) which satisfies the aforementioned properties and propose a point and an interval estimator for the CP. We illustrate our methods using a clinical trial example in Section 3. In Section 4 we study the performance of these estimators through simulations. A discussion can be found in Section 5.
Competing probability and its point and interval estimator

Competing probability and its point estimator
, X k and Y k are independent random variables with CDF F k and G k , respectively. Therefore, an unbiased estimator for π k iŝ
Clearly, the vE statistic is also equivalent to
where
a kπk is an unbiased estimator for π. In other words, π is the population parameter the vE statistic is intended to estimate. We term π as the competing probability (CP) for comparing Treatment A with Treatment B. To our knowledge, the term of CP has not been used by other researchers for the van Elteren test. The CP can be interpreted as the treatment effect averaging across strata. Moreover, the CP under the null hypothesis is equal to 0.5. Therefore, when a significant vE p-value is observed, we can compareπ with 0.5. For example, if larger response values indicate better treatment effect andπ > 0.5, then Treatment A is better than Treatment B. In addition, when the number of strata is 1 (k = 1), the CP becomes the Area under the ROC Curve (AUC) [1] , which is a well-known quantity commonly used in diagnostics and PK studies. So far we have accomplished the first goal we have set forth in the beginning. In the next section we develop an interval estimator for the CP.
Confidence interval estimator for the competing probability
In this section we derive a Wald-type confidence interval (CI) estimator for the CP π = a k π k based on its unbiased estimatorπ = a kπk . Because the variance in Eq. (1) is computed under the null hypothesis of no treatment effect, it cannot be directly used to construct CIs. The variance ofπ k under the alternative hypothesis can be computed using a formula provided in DeLong et al. [3] . Specifically, define
where function δ is the same as previously defined. The quantity u k,i is an estimate of the competing probability for comparing a single observation x k,i with a group of observations {y k,j , j = 1, . . . n k }. It measures the relative rank of the ith observation of Treatment A in the Treatment B. The interpretation of v k,j is similar. Then, the variance of π k can be estimated aŝ To construct a 100(1 − α)% CI for π, we first compute a z-statistic using a logit transformation:
Then, a 100(1 − α)% CI for π can be constructed as
, and Z 1−α/2 is the (1 − α/2)th quantile of the standard normal distribution. If the estimateπ is equal to zero or one for a data set, then a 100(1 − α)% CI for π can be constructed asπ ± Z 1−α/2 V (π) without going through the logit transformation. We used the logit transformation so that the range of logit (π) spans the real line and the asymptotic theory works better. The R code is also downloadable from a public website and the URL is provided in the Appendix.
A real data example
In this section we apply our point and interval estimation method of the CP to a real clinical trial example with ordinal data. We consider data from a clinical trial described in Cardozo et al. [2] and Zhao et al. [11] . This double-blind clinical trial investigated the efficacy of duloxetine compared with placebo in women with moderate to severe stress urinary incontinence waiting for continence surgery. A total of 109 patients were randomized in a ratio of 1:1 to placebo (54) or duloxetine (55). At baseline the patients were grouped into two disease severity strata (BIEF < 28 or BIEF 28) where BIEF is the baseline Incontinence Episode Frequency per week. One of the important secondary efficacy measures in the study is the endpoint rating of the Patient Global Impression of Improvement (PGI-I) questionnaire. The PGI-I questionnaire asks the patients to check the one number that best describes how their urinary tract condition is now, compared with how it was before they began taking medication in this study: 1 (very much better), 2 (much better), 3 (a little better), 4 (no change), 5 (a little worse), 6 (much worse), 7 (very much worse). A derived efficacy measure from the PGI-I is the modified PGI-I rating: 1 (= better; if PGI-I = 1, 2, or 3), 2 (= no change; if PGI-I = 4), 3 (= worse; if PGI-I = 5, 6, or 7). The modified PGI-I was analyzed by the van Elteren test with baseline severity strata as the stratification factor. Note that in general, reducing the original scale (PGI-I) to a new scale (modified PGI-I) with fewer categories is not a good statistical practice as some information could be lost in the process. However, this was done in Cardozo et al. [2] and was well-received by the incontinence society, and we will follow that just for the purpose of illustrating the calculation and interpretation of competing probability.
The observed counts and proportions in the 2 × 3 table of treatment by modified PGI-I responses broken down by BIEF status are displayed in Table 1 . Although a 2-sided 0.05 α level was considered to be significant in the study, here we use a 2-sided 0.1 α level for the purpose of illustration. The vE p-value is 0.078, indicating the result is significant at 0.1 α level. The CP that duloxetine has a smaller (i.e., better) PGI-I response than the placebo group as well as 90% CIs are presented in Table 1 . The overall CP is 0.59 and the 90% CI is (0.51, 0.67). Because the lower confidence limit is greater than 0.5, the study shows that the duloxetine patients have a significantly better PGI-I response than placebo patients at 0.1 α level, which is consistent with the significant vE p-value.
A simulation study
In this section we conduct a simulation study to examine the performance of the point and interval estimators for CP developed in Section 3. In the simulation, we generate an ordinal response variable taking three values (1, 2, and 3) in two strata. In addition, we consider 95% CIs and fix the randomization ratio between two treatments to be 1:1 within each stratum.
We use three values for the total sample size (N = 50, 100, and 200) and 2 stratum fractions (SF = (0.2, 0.8), and (0.5, 0.5)). We choose 3 sets of contingency table proportions for the response variable as displayed in Table 2 . The proportions are chosen such that they may differ across the two strata but the stratum specific CPs are the same. In other words, there are stratum effects, but the treatment effects are the same across strata. In Set 1, there are no treatment effects; in Set 2, the treatment effect is moderate; in Set 3, the treatment effect is pronounced. In total, there are 18 simulation scenarios.
For each scenario, we generate 5,000 datasets. The true CP, estimated CP, coverage probabilities and average lengths of the interval estimator are computed. Figure 1 displays the density plots of the 5,000 point estimates for all 18 scenarios. From the density plots we see the point estimates are symmetric and centered about the true CP, except for the scenario where CP is close to 0 (CP = 0.1) and stratum fractions are unbalanced (SF = (0.2, 0.8)). As expected, for each simulation scenario, the variability of the density plot decreases as the sample size increases. Table 3 presents the coverage probabilities and average lengths of the confidence interval estimator. Across all 18 scenarios the coverage probabilities are approximately equal to the nominal 95% level except for the two scenarios where CP is close to 0 (CP = 0.1) and sample size is small (N = 50). The stratum fractions have little effects on the coverage probabilities and average lengths. As expected, the average lengths decrease as the total sample sizes increase.
Discussion
In this paper we have proposed a CP concept which can be used to determine which treatment is better when a significant vE p-value is observed. In addition, we developed point and interval estimation methods for CP and simulations showed that the point and interval estimators work very well.
We note that this CP concept is different from the location shift parameter commonly associated with the WMW test and estimated by the Hodges-Lehmann method. The location shift parameter is not inherently related to the WMW test and should be used very rarely. In addition, there is no similar location shift parameter defined for the vE test. Therefore, we propose to report CP as a measure of treatment effect rather than the location shift parameter. In addition, we recommend the simultaneous output of CP estimates for standard software package when vE p-value is computed.
